Literature DB >> 11155543

Miller Fisher syndrome: axonal, demyelinating or both?

S N Scelsa1, S Herskovitz.   

Abstract

Controversy exists concerning whether Miller Fisher syndrome (MFS) is the result of a predominantly axonal or demyelinating polyneuropathy and whether the Guillain-Barré syndrome variant of acute ataxia and areflexia without ophthalmoplegia, ataxic Guillain-Barré syndrome (atxGBS), has a distinct pathophysiology. We explored these issues by reviewing the electrophysiologic features of 6 patients with MFS and 2 patients with atxGBS. EMG laboratory records were reviewed and electrophysiologic findings were categorized as axonal or demyelinating neuropathy using previously defined criteria. Of the 6 patients with MFS, 5 had electrophysiologic evidence suggestive of an axonal, predominantly sensory polyneuropathy; only 1 patient met criteria for demyelinating polyneuropathy. Both patients with atxGBS had demyelinating sensorimotor polyneuropathy. Electrophysiologic abnormalities in MFS typically suggest a predominantly axonal, sensory polyneuropathy, though demyelinating forms occur and may be under-diagnosed using current criteria. AtxGBS, in our experience, is a predominantly demyelinating polyneuropathy.

Entities:  

Mesh:

Year:  2000        PMID: 11155543

Source DB:  PubMed          Journal:  Electromyogr Clin Neurophysiol        ISSN: 0301-150X


  2 in total

1.  Miller Fisher syndrome--a presenting clinical manifestation of lung cancer in a previously apparently healthy individual.

Authors:  Tünde Csépány; Judit Boczán; Mária T Magyar; Sándor Molnár; László Csiba; Judit Décsy; Judit Tóth; Szabolcs Felszeghy; Szabolcs Szakáll; Zsolt Szentkereszty; Dániel Bereczki
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

Review 2.  Miller Fisher syndrome associated with COVID-19: an up-to-date systematic review.

Authors:  Zheng Li; Xingye Li; Jianxiong Shen; Matthew T V Chan; William Ka Kei Wu
Journal:  Environ Sci Pollut Res Int       Date:  2021-03-06       Impact factor: 4.223

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.